Literature DB >> 6376024

Non-insulin-dependent diabetes mellitus: a clinical strategy.

J S Skyler.   

Abstract

In non-insulin-dependent diabetes mellitus (NIDDM), there are defects in both islet beta cell function (insulin secretion) and in insulin action. It is proposed that these may be two manifestations of a common defect involving glucose metabolism. These may be a consequence of some aspect of the insulin-deficient state, e.g., insulin deficiency or hyperglycemia. This implies that the defects of NIDDM are both "feed-forward" (i.e., they lessen with improvement of the metabolic state) and "fail-backward" (i.e., emerging defects in islet beta cell function and insulin action aggravate each other). A subclassification of NIDDM is proposed, based on presumed pathophysiologic defects. This subclassification divides patients, on the basis of fasting (basal) plasma glucose and postprandial glucose response to meals, into four categories: mild, moderate, severe, and very severe. The therapeutic strategies for these four categories are slightly different. Diet and exercise are always a component of therapy. Sulfonylureas are used, as needed, in patients with mild or moderate NIDDM. Basal insulin therapy may be used in moderate NIDDM. Some form of around-the-clock insulin therapy is used for patients with severe NIDDM. Very severe NIDDM is treated by more intensive insulin therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376024

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

Authors:  B H Wolffenbuttel; L Nijst; J P Sels; P P Menheere; P G Müller; A C Kruseman
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Insulin secretion and insulin sensitivity defects are a common feature of mild, clinically homogeneous, recently diagnosed type II (non-insulin-dependent) diabetics.

Authors:  E Pisu; A Lombardi; D De Benedictis; C Bozzo; E Chiara; C Baggiore; A Bruno; L Cravero; G Pagano; G Lenti
Journal:  Acta Diabetol Lat       Date:  1986 Jul-Sep

3.  Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus.

Authors:  A M Borissova; D G Koev; M G Minev; F G Martinova; P I Gencova; G G Kirilov; J Arnaudov
Journal:  Acta Diabetol Lat       Date:  1991 Jan-Mar

Review 4.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

5.  The effects of diet and exercise in the treatment of non-insulin dependent diabetes mellitus.

Authors:  K B Huh; H S Park; H M Kim; S K Lim; K R Kim; H C Lee
Journal:  Korean J Intern Med       Date:  1986-07       Impact factor: 2.884

6.  Defining Heterogeneity Among Women With Gestational Diabetes Mellitus.

Authors:  Camille E Powe; Marie-France Hivert; Miriam S Udler
Journal:  Diabetes       Date:  2020-08-25       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.